Interleukin ‐6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression

In conclusion, our results elucidate that interleukin‐6/STAT3 activation can increase PTTG1 expression and, consequently, promote the resistance to ADT in CRPC by inducing EMT and increasing the cancer stem cell population, suggesting that PTTG1 may be a novel therapeutic target for CRPC. In the present study, we found that pituitary tumor transforming 1 (PTTG1) overexpression promoted the resistance to androgen‐deprivation therapy (ADT) in androgen‐dependent prostate cancer cell lines LNCaP via inducing EMT and increasing CD44+CD24− cancer stem cell population. Furthermore, PTTG1 expression was regulated by IL‐6 via activated STAT3 directly binding to the region −500 to +1 of PTTG1 promoter in LNCaP cells. Taken together, these results indicated that PTTG1 can be regulated by IL‐6/STAT3 and play a vital role in the development and progression of castration‐resistant prostate cancer (CRPC), suggesting that PTTG1 may be a novel therapeutic target for CRPC.
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research